This website is for US healthcare professionals

close-icon

Log In to Bolder Science

or

Don't have an account? Sign Up

close-icon

Please enter your email address.

You will receive a link to create a new password via email.

Log In

close-icon

Create an Account

or
  • 8 characters minimum
  • First character may not be a number
  • Last character may not be a number
close-icon

Welcome and thank you for creating an account!

At Bolder Science, we want your clinical trial search experience to be the best it can be. Complete the following prompts to easily find the trials you are interested in and see trials recruiting near you. You can adjust these selections in your dashboard after creating your account.

Condition Categories

Condition categories are pulled directly from ClinicalTrials.gov. Choose 1 or more condition categories that you are interested in:

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

Set a default location

Back
Filter 590 trials Clear all
Filter by:

Pevonedistat, Azacitidine, and Venetoclax for the Treatment of Patients With Acute Myelogenous Leukemia

  • Status Recruiting
    Recruiting
  • Condition Acute Myelogenous Leukemia
    Acute Myelogenous Leukemia
  • Phase Phase 1
    Phase 1
INTERVENTION

Drug: Azacitidine, Drug: Venetoclax, Drug: Pevonedistat

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Azacitidine, Drug: Venetoclax, Drug: Pevonedistat

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Mayo Clinic, Rochester, Minnesota, United States

Brief Summary

This is a phase Ib study with a 3 + 3 dose escalation design followed by a dose-expansion phase.

Randomised Study of Oral Azacitidine vs Placebo Maintenance in AML or MDS Patients After Allo-SCT

  • Status Recruiting
    Recruiting
  • Condition Acute Myeloid Leukemia, Myelodysplasia
    Acute Myeloid Leukemia, Myelodysplasia
  • Phase Phase 3
    Phase 3
INTERVENTION

Drug: Oral azacitidine, Drug: Matched placebo

Eligibility
  • Ages: 16 Years and older (Child, Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Oral azacitidine, Drug: Matched placebo

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Heartlands Hospital, Birmingham, United Kingdom

Brief Summary

This study will evaluate a new maintenance therapy with the aim of improving the outcome of patients with acute myeloid leukaemia (AML) and myelodysplasia (MDS) after stem cell transplantation.

A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)

  • Status Recruiting
    Recruiting
  • Condition Acute Myeloid Leukemia
    Acute Myeloid Leukemia
  • Phase Phase 1
    Phase 1
INTERVENTION

Drug: ASTX660, Drug: ASTX727

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: ASTX660, Drug: ASTX727

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Smilow Cancer Hospital, New Haven, Connecticut, United States

Brief Summary

To evaluate the safety, pharmacokinetics (PK), and efficacy of ASTX660 when given alone and in combination with ASTX727 in participants with relapsed/refractory (R/R) acute myeloid leukemia (AML). The duration of the study is expected to be approximately 30 months.

US Study of UM171-Expanded CB in Patients With High Risk Leukemia/Myelodysplasia

  • Status Recruiting
    Recruiting
  • Condition Cord Blood Transplant, High Risk Hematological Malignancy
    Cord Blood Transplant, High Risk Hematological Malignancy
  • Phase Phase 2
    Phase 2
INTERVENTION

Biological: ECT-001-CB (UM171-Expanded Cord Blood Transplant)

Eligibility
  • Ages: 18 to 65 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Biological: ECT-001-CB (UM171-Expanded Cord Blood Transplant)

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Fred Hutchinson / University of Washington Cancer Consortium, Seattle, Washington, United States

Brief Summary

Cord blood (CB) transplants are an option for patients lacking an HLA identical donor but are hampered by low cell dose, prolonged aplasia and high transplant related mortality. UM171, a novel and potent agonist of hematopoietic stem cell self renewal could solve this major limitation, allowing for CB's important qualities as lower risk of chronic GVHD and relapse to prevail. In a previous trial (NCT02668315), the CB expansion protocol using the ECT-001-CB technology (UM171 molecule) has proven to be technically feasible and safe. UM171 expanded CB was associated with a median neutrophil recovery at day (D)+18 post transplant. Amongst 22 patients who received a single UM171 CB transplant with a median follow-up of 18 months, risk of TRM (5%) and grade 3-4 acute GVHD (10%) were low. There was no moderate-severe chronic GVHD. Thus, overall and progression free survival at 12 months were impressive at 90% and 74%, respectively. The UM171 expansion protocol allowed access to smaller, better HLA matched CBs as >80% of patients received a 6-7/8 HLA matched CB. Interestingly there were patients with high-risk hematologic malignancies and multiple comorbidities (5 patients who had already failed an allogeneic transplant and 5 patients with refractory/relapsed acute leukemia/aggressive lymphoma). Despite this high risk population, progression was 20% at 12 months. This new study seeks to test a similar strategy in a group of patients with high risk acute leukemia/myelodysplasia.

Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia

  • Status Recruiting
    Recruiting
  • Condition Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukaemia Recur...
    Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukaemia Recur...
  • Phase Early Phase 1
    Early Phase 1
INTERVENTION

Drug: INA03 administration

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: INA03 administration

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Institut Paoli-Calmettes, Marseille, Bouches-du Rhône, France

Brief Summary

This Phase 1 Study is an open-label, non-randomized, dose escalation, safety, efficacy, pharmacokinetic, and pharmacodynamic evaluation study of INA03 administered as a single agent IV infusion every 2 weeks to patients ≥18 years of age with R/R AML, MLL, or ALL. The study will be performed in 2 parts: a Dose Titration for Day 1 study (Part 1) followed by a Dose Escalation Part (Part 2) of INA03 used as monotherapy.

CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients

  • Status Recruiting
    Recruiting
  • Condition Acute Myeloid Leukemia, Myeloid Neoplasm
    Acute Myeloid Leukemia, Myeloid Neoplasm
  • Phase Phase 2
    Phase 2
INTERVENTION

Other: Questionnaire Administration, Other: Quality-of-Life Assessment, Biological: Recombinant Granulocyte Colony-Stimulating Factor, Drug: Mitoxantrone, Drug: Liposome-encapsulated Daunorubicin-Cytarabine, Drug: Cladribine, Drug: Cytarabine

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Other: Questionnaire Administration, Other: Quality-of-Life Assessment, Biological: Recombinant Granulocyte Colony-Stimulating Factor, Drug: Mitoxantrone, Drug: Liposome-encapsulated Daunorubicin-Cytarabine, Drug: Cladribine, Drug: Cytarabine

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Brief Summary

This phase II trial studies how well CPX-351 or the CLAG-M regimen (consisting of the drugs cladribine, cytarabine, G-CSF, and mitoxantrone) works in treating medically less-fit patients with acute myeloid leukemia or other high-grade myeloid neoplasms. Drugs used in chemotherapy, such as CPX-351, cladribine, cytarabine, G-CSF, and mitoxantrone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving CPX-351 or the CLAG-M regimen at doses typically used for medically-fit patients with acute myeloid leukemia may work better than reduced doses of CPX-351 in treating medically less-fit patients with acute myeloid leukemia or other high-grade myeloid neoplasms.

Allogenic NK Cell Transfusion Azacitidine MDS-EB

  • Status Not yet recruiting
    Not yet recruiting
  • Condition MDS-EB
    MDS-EB
  • Phase Phase 1 Phase 2
    Phase 1 Phase 2
INTERVENTION

Biological: Allogeneic NK cell regimen group

Eligibility
  • Ages: 15 to 70 Years (Child, Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Biological: Allogeneic NK cell regimen group

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

The 2nd Hospital of Shandong University, Jinan, Shandong, China

Brief Summary

The aim of this investigation was to assess safety and efficacy of allogenic NK cells therapy for refractory MDS-EB.

Efficacy and Safety Evaluation of IBI188 in Combination With Azacitidine in Treatment of Patients With Acute Myeloid Leukemia

  • Status Recruiting
    Recruiting
  • Condition Acute Myeloid Leukemia
    Acute Myeloid Leukemia
  • Phase Phase 1 Phase 2
    Phase 1 Phase 2
INTERVENTION

Drug: IBI188, Drug: Azacitidine

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: IBI188, Drug: Azacitidine

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

Brief Summary

The study is to evaluate safety, tolerability and composite CR of IBI188 plus azacitidine in acute myeloid leukemia

A Study of APG-115 Alone or in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML)

  • Status Recruiting
    Recruiting
  • Condition Acute Myeloid Leukemia, AML
    Acute Myeloid Leukemia, AML
  • Phase Phase 1 Phase 2
    Phase 1 Phase 2
INTERVENTION

Drug: APG-115, Drug: 5-azacitidine

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: APG-115, Drug: 5-azacitidine

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

MD Anderson, Houston, Texas, United States

Brief Summary

To determine the safety and tolerability of APG-115 combined with 5-azacitidine (5-AZA) in patients with relapsed/refractory AML

Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

  • Status Recruiting
    Recruiting
  • Condition Therapy-Related Myelodysplastic Syndrome, Refractory Myelodysplas...
    Therapy-Related Myelodysplastic Syndrome, Refractory Myelodysplas...
  • Phase Phase 1 Phase 2
    Phase 1 Phase 2
INTERVENTION

Drug: Azacitidine, Drug: Venetoclax

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Azacitidine, Drug: Venetoclax

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

M D Anderson Cancer Center, Houston, Texas, United States

Brief Summary

This phase I/II trial investigates the side effects and best dose of venetoclax when given together with azacitidine and to see how well it works in treating patients with high-risk myelodysplastic syndrome or chronic myelomonocytic leukemia that has come back (relapsed) or has not responded to treatment (refractory). Venetoclax may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving venetoclax and azacitidine together may help to control myelodysplastic syndrome or chronic myelomonocytic leukemia.